S&P 500
5.029,11 -42,52 (-0,84%) Nasdaq
15.519,58 -193,16 (-1,23%) NIKKEI 225
37.628,48 -831,60 (-2,16%) Dólar/Euro
1,0732 +0,0031 (+0,29%) Petróleo Brent
87,91 -0,11 (-0,12%) Bitcoin EUR
59.806,09 -472,65 (-0,78%)
Enanta Pharmaceuticals, Inc. (ENTA)
Enanta Pharmaceuticals, Inc.
500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800
https://www.enanta.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 145
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1,25M | 2,03M | 1956 |
| Mr. Paul J. Mellett Jr. | Senior VP of Finance & Administration and CFO | 666,84k | 529,98k | 1955 |
| Dr. Yat Sun Or Ph.D. | Senior VP of Research & Development and Chief Scientific Officer | 729,31k | 424,85k | 1952 |
| Mr. Nathaniel S. Gardiner J.D. | Consultant | 672,67k | 49,14k | 1954 |
| Mr. Brendan Luu | Senior Vice President of Business Development | 622,86k | N/A | 1975 |
| Ms. Jennifer Viera | Senior Director of Investor Relations & Corporate Communications | N/A | N/A | N/A |
| Ms. Tara Lynn Kieffer Ph.D. | Senior Vice President of New Product Strategy & Development | 496,85k | N/A | 1978 |
| Dr. Scott T. Rottinghaus M.D. | Senior VP & Chief Medical Officer | 616,73k | N/A | 1974 |
Descripción
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Gobierno corporativo
El ISS Governance QualityScore de Enanta Pharmaceuticals, Inc., a día 1 de abril de 2024, es 5. Las puntuaciones base son Auditoría: 3; Tablero: 4; Derechos de los accionistas: 8; Compensación: 7.
